Emerging Company Profile
Blackfynn: optimizing trial design for neurodegenerative therapies
Emerging Company Profile: Blackfynn aims to bring deprioritized late-stage neurodegenerative disease programs to market
Blackfynn is using its platform to redesign trials for neurodegenerative therapies, starting with an in-licensed Phase III-ready asset for Parkinson’s disease.
Mar 20, 2021 | 1:38 AM GMT
Blackfynn has pivoted from a data service company to a drug developer that in-licenses clinical assets